Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ:ILMN)

123.54 +24.53 (+24.78%)
Official Closing Price Updated: 4:15 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Illumina, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
35 36 Next >
Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina
Rosenblatt boosted the price target on Amazon.com, Inc. (NASDAQ: AMZN) from $118 to $103. Rosenblatt analyst Barton Crockett maintained the stock with a Neutral rating. Amazon shares fell 4.3% to close... 
Via Benzinga
$1000 Invested In Illumina 15 Years Ago Would Be Worth This Much Today
Illumina (NASDAQ:ILMN) has outperformed the market over the past 15 years by 8.91% on an annualized basis producing an average annual return of 15.72%. Currently, Illumina has a market capitalization... 
Via Benzinga
What 12 Analyst Ratings Have To Say About Illumina
Within the last quarter, Illumina (NASDAQ:ILMN) has observed the following analyst ratings: 
Via Benzinga
11 Analysts Have This to Say About Illumina
Within the last quarter, Illumina (NASDAQ:ILMN) has observed the following analyst ratings: 
Via Benzinga
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
A mixed jobs report and heavy earnings swung stocks. 
Via Investor's Business Daily
This Growth Stock Rose Last Week. Is It Still a Buy?
Illumina is the dominant player in gene sequencing. 
Via The Motley Fool
Musk Reportedly Suspends Twitter Work On Crypto Wallet, Boeing's Jeppesen Hit By Potential Ransomware Attack, Lyft Cuts Workforce: Top Stories Friday, Nov. 04
Reuters 
Via Benzinga
Illumina's Q3 Profits Hit By Impairment Of Almost $4B, Cuts Annual Guidance
 
Via Benzinga
Illumina Plummets On Light Earnings Guidance Despite Quarterly Beat
Illumina posted a wide miss for its full-year adjusted earnings outlook, leading shares to tumble after hours. 
Via Investor's Business Daily
$1000 Invested In Illumina 20 Years Ago Would Be Worth This Much Today
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 18.98% on an annualized basis producing an average annual return of 26.53%. Currently, Illumina has a market capitalization... 
Via Benzinga
Ranking 7 Top Tech Stocks to Buy From Biggest to Smallest
Although "Big Tech" is currently struggling, but there are still many good top tech stocks to buy at this point. 
Via InvestorPlace
What 12 Analyst Ratings Have To Say About Illumina
Analysts have provided the following ratings for Illumina (NASDAQ:ILMN) within the last quarter: 
Via Benzinga
Wall Street Is Still Bullish on This Punished Growth Stock -- Is It a Buy?
Bionano's stock price movements have little to do with its successes. 
Via The Motley Fool
Illumina Gains But Lags Market: What You Should Know
In the latest trading session, Illumina (ILMN) closed at $220.57, marking a +0.25% move from the previous day. This move lagged the S&P 500's daily gain of 1.19%. Meanwhile, the Dow gained 1.34%, and... 
Via Talk Markets
Companion Diagnostics Industry to Witness Emergence of Players Including Abbott Laboratories, - bioMerieux, Illumina, Agilent Technologies, and Thermo Fisher Scientific –
This press release was orginally distributed by SBWire 
Via ReleaseWire
Companion Diagnostics Industry to Witness Emergence of Players Including Abbott Laboratories, - bioMerieux, Illumina, Agilent Technologies, and Thermo Fisher Scientific –
London, UK -- (SBWIRE) -- 10/18/2022 -- The latest publication titled Companion Diagnostics – Thematic Research has been added to GlobalData Plc report store. Companion diagnostics (CDx) are molecular... 
Via SBWire
Universal Sequencing Technology Corporation Announces High-Throughput Solution For NGS Library Preparation
UST releases high-throughput solution enabling second-generation short-read sequencers to produce long-range results in greater capacity.CARLSBAD, Calif. - Oct. 24, 2022 - PRLog -- Universal Sequencing... 
Via PRLog
Topics Intellectual Property
Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery
 
Via Benzinga
Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely
One analyst doubts any deal could come to fruition. If it did, it would make sense. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Illumina Stock In The Last 20 Years
Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 19.07% on an annualized basis producing an average annual return of 26.54%. Currently, Illumina has a market capitalization... 
Via Benzinga
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing... 
Via FinancialNewsMedia
Twitter, Ford And Other Big Gainers From Tuesday
U.S. stocks closed sharply higher with the Dow Jones jumping more than 800 points on Tuesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Looking At Illumina's Recent Whale Trades
A whale with a lot of money to spend has taken a noticeably bearish stance on Illumina. Looking at options history for Illumina (NASDAQ:ILMN) we detected 26 strange trades. 
Via Benzinga
Why This Illumina Analyst Is Bullish About NovaSeq X+
Illumina, Inc.’s (NASDAQ: ILMN) NovaSeq X Plus is likely to become “the ultimate genome machine,” lending upside in 2024 and beyond, according to SVB Securities. 
Via Benzinga
Is Illumina Still the Gamechanger in Genomics Sequencing?
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused 
Via MarketBeat
Topics Earnings Economy Lawsuit
CD Genomics RNA-Solutions Platform Now Provides Whole Transcriptome Sequencing Service
Via Get News
12 Analysts Have This to Say About Illumina
Over the past 3 months, 12 analysts have published their opinion on Illumina (NASDAQ:ILMN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
3 Biotech Stocks to Sell in October
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market. 
Via InvestorPlace
What Are Whales Doing With Illumina
Someone with a lot of money to spend has taken a bullish stance on Illumina (NASDAQ:ILMN). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Netflix, Biogen And Other Big Gainers From Wednesday
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.